Article: FDA ISSUES HISMANAL WARNING

 
 FDA ISSUES HISMANAL WARNING 
WASHINGTON, July 20 /PRNewswire/ -- The Food and Drug 

Administration and Janssen Pharmaceutica, manufacturer of the prescription antihistamine drug Hismanal, today announced that Janssen will inform doctors and other health professionals of cardiovascular risks to patients who exceed the recommended dose.

 
Rare cases of serious cardiovascular events, including death, cardiac arrest and arrhythmias, were reported in patients exceeding the recommended dose of 10 mg (one tablet) per day.  While the majority of these cardiovascular events have occurred in patients who have greatly exceeded the recommended ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!